ZenCort Tablets
Deflazacort 6 mg
Clinical Differentiators & Advantages
PCD Franchise Distribution
Verify if exclusive marketing and distribution rights for ZenCort Tablets are currently vacant in your target district.
Active Chemical Compounds & Molecular Architecture
Validated chemical entities, 2D skeletal bond diagrams, empirical molecular formulas, and receptor-level modes of action
Third-generation oxazoline corticosteroid providing potent systemic anti-inflammatory suppression with improved bone safety.
Approved Clinical Indications & Disease Burden
Pharmacodynamic Mechanism of Action
Third-generation oxazoline derivative of prednisolone. Deflazacort binds to glucocorticoid receptors to suppress lymphocyte proliferation, inhibit cytokine transcription, and modulate inflammatory cell migration. Its unique chemical structure confers high glucocorticoid anti-inflammatory potency while showing minimal affinity for mineralocorticoid receptors, resulting in significantly less bone mineral loss, reduced diabetogenic risk, and lower sodium/water retention.
Dosage & Administration Protocol
Initial dose 6 to 90 mg/day depending on clinical severity, tapered under specialist care.
Precautions, Warnings & Contraindications
B2B Commercial & Shipping Metrics
Moisture-sealed 5-ply export corrugation
Includes visual aids & promotional inputs
Private label & institutional supply
Standard pharmaceutical commercial tariff
Certificate of Analysis (COA), Stability Study Reports (Zone IVb), Finished Product Specs (FPS), and Material Safety Data Sheet (MSDS).